Illumina to buy PacBio for $1.2 billion

Create PDF

January 2019—Illumina announced it will acquire Pacific Biosciences for approximately $1.2 billion. With this acquisition, Illumina will be positioned to provide integrated workflows and novel innovations that bring together both Illumina’s short-read sequencing platforms and PacBio’s long-read sequencing capabilities to help researchers advance their discoveries faster and to help clinicians offer new tests economically. Illumina expects to close the transaction in mid-2019.